Phase 1/2 clinical design, as well as EU/US access and commercial strategy.
Phase 1/2 clinical design and EU/US access as well as commercial strategy.
Portable imaging device validation and early hospital adoption strategy (Europe focus).
Market sizing, regulatory strategy, clinical development, and investment planning for a sustained-release ophthalmic therapy in a rare disease indication (US focus).
Full market assessment, regulatory strategy, and clinical development plan and go-to-market plan for a sustained-release delivery device (US and Europe focus).